Sessions

Join us for back-to-back fireside chats with national healthcare policy experts who offer differing perspectives on how the GOP’s sweeping control of the federal government may impact senior housing, long-term care and health care more broadly.  We’ll explore how the new administration’s interpretation of the Chevron ruling could influence regulatory decision-making and private sector innovation, the future of value-based care and Medicare Advantage and the implications for operators and investors, potential changes to CMS directives, strategies to address the workforce crisis, and how tax policy may impact reimbursement rates.

Dr. Scott Gottlieb is a physician, investor and author who served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017-2019 under President Donald J. Trump. Previously he served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and, prior to that, as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services.  Dr. Gottlieb is currently a senior fellow at the American Enterprise Institute for Public Policy Research and a partner at the venture capital firm New Enterprise Associates. He serves on the boards of Pfizer,Inc., Illumina, Inc., and TempusAI, and is also a regular contributor to CNBC and CBS News’ Face the Nation.

Bringing an alternate point of view is Andy Slavitt, former Senior Advisor to the Biden administration on COVID response and former Acting Administrator for the Centers for Medicare & Medicaid Services under President Obama. He is a founder and general partner of Town Hall Ventures, which invests in companies that transform access and equitable care for underserved Americans.  Mr. Slavitt also serves on the boards of Bright Health and Cityblock Health.